Skip to content
Research Article Open access CC BY 4.0

Fetal and Neonatal Alloimmune Thrombocytopenia: A Concise Review

Samson Ojedokun, Taiwo Oloyede, Ayobami Alabi, Oluwaseyi Oke, Abraham Akinbola, Olawumi kofoworade, Olanike Oladibu

Asian Journal of Pediatric Research · pp. 99–103 · Published 25 Nov 2023

10.9734/ajpr/2023/v13i4296

Abstract

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare disease resulting from the effect of maternal alloantibodies on fetal human platelet antigens HPAs which could lead to severe haemorrhage. An antibody from mother reacting against a defined platelet alloantigen has been identified as the aetiology of platelet destruction in an infant with this condition and several other platelet-specific antigens were implicated to be capable of initiating maternal immunization during pregnancy leading to fetal platelet destruction. However, in most cases of maternal sensitizations the exposure to fetal blood usually occur during delivery, resulting to thrombocytopenia in the newborn. Current management of fetal and neonatal alloimmune thrombocytopenia in the next pregnancy involves administration of intravenous immune globulin and steroids during antenatal for mothers with previous history or those at risk. Some advances has been suggested in the line of management and these include testing of cell-free fetal DNA obtained from maternal blood to determine the fetal human platelet antigen genotype, the creation of a prophylactic product; a platelet equivalent of Rhesus immune globulin and the development of neonatal Fc receptor inhibitors to replace the current medical therapy administered to pregnant women with an affected fetus. FNAIT is a devastating complication of pregnancy that can present with difficult diagnostic and treatment challenges. Hence, a need for surveillance.

FNAIT perinatal death alloimmune thrombocytopenia

References (12)

  1. 1 Platelets and Primary Haemostasis [DOI]
  2. 2 Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management [DOI]
  3. 3 Causes of perinatal mortality and associated maternal complications in a South African province: challenges in predicting poor outcomes [DOI]
  4. 4 New developments in fetal and neonatal alloimmune thrombocytopenia [DOI]
  5. 5 Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia: induction of antibody‐mediated immune suppression and prevention of severe clinical complications in a murine model [DOI]
  6. 6 Fetal and neonatal alloimmune thrombocytopenia: evidence based antenatal and postnatal management strategies [DOI]
  7. 7 Prevalence and clinical significance of low‐avidity HPA‐1a antibodies in women exposed to HPA‐1a during pregnancy [DOI]
  8. 8 Fetal and Neonatal Alloimmune Thrombocytopenia—New Prospects for Fetal Risk Assessment of HPA-1a–Negative Pregnant Women [DOI]
  9. 9 Clinical characteristics of human platelet antigen (HPA)‐1a and HPA‐5b alloimmunised pregnancies and the association between platelet HPA‐5b antibodies and symptomatic fetal neonatal alloimmune thrombocytopenia [DOI]
  10. 10 Non-invasive risk-assessment and bleeding prophylaxis with IVIG in pregnant women with a history of fetal and neonatal alloimmune thrombocytopenia: management to minimize adverse events [DOI]
  11. 11 Determinants of perinatal mortality in public secondary health facilities, Abuja Municipal Area Council, Federal Capital Territory, Abuja, Nigeria [DOI]
  12. 12 Predicting risk severity and response of fetal neonatal alloimmune thrombocytopenia [DOI]

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

56

Page views

0

PDF downloads

31

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.